4.3(top 10%)
impact factor
1.8K(top 10%)
papers
40.8K(top 10%)
citations
80(top 10%)
h-index
4.5(top 10%)
impact factor
2.3K
all documents
43.5K
doc citations
110(top 10%)
g-index

Top Articles

#TitleJournalYearCitations
1Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancerProstate Cancer and Prostatic Diseases2006373
2Components of the metabolic syndrome—risk factors for the development of benign prostatic hyperplasiaProstate Cancer and Prostatic Diseases1998260
3Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy settingProstate Cancer and Prostatic Diseases2010255
4Proteinchip® surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixturesProstate Cancer and Prostatic Diseases1999239
5ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratificationProstate Cancer and Prostatic Diseases2010227
6Pathologic progression of autochthonous prostate cancer in the TRAMP modelProstate Cancer and Prostatic Diseases1999222
7Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerationsProstate Cancer and Prostatic Diseases2019215
8Increasing incidence of metastatic prostate cancer in the United States (2004–2013)Prostate Cancer and Prostatic Diseases2016205
9Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006Prostate Cancer and Prostatic Diseases2011183
10Clinical phenotyping in chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis: a management strategy for urologic chronic pelvic pain syndromesProstate Cancer and Prostatic Diseases2009180
11Safety and efficacy of resistance exercise in prostate cancer patients with bone metastasesProstate Cancer and Prostatic Diseases2013179
12Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigationProstate Cancer and Prostatic Diseases2009174
13A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancerProstate Cancer and Prostatic Diseases2013170
14Role of zinc in the pathogenesis and treatment of prostate cancer: critical issues to resolveProstate Cancer and Prostatic Diseases2004158
15Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studiesProstate Cancer and Prostatic Diseases2013155
16Novel antiproliferative flavonoids induce cell cycle arrest in human prostate cancer cell linesProstate Cancer and Prostatic Diseases2006150
17Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistanceProstate Cancer and Prostatic Diseases2015149
18The effects of curcumin on the invasiveness of prostate cancer in vitro and in vivoProstate Cancer and Prostatic Diseases2006148
19Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targetingProstate Cancer and Prostatic Diseases2016142
20Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrenceProstate Cancer and Prostatic Diseases2010139
2118F-fluorocholine for prostate cancer imaging: a systematic review of the literatureProstate Cancer and Prostatic Diseases2012139
22A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy resultProstate Cancer and Prostatic Diseases2015138
23Impact of diet on prostate cancer: a reviewProstate Cancer and Prostatic Diseases2005137
24Wnt signalling and prostate cancerProstate Cancer and Prostatic Diseases2005135
25Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancerProstate Cancer and Prostatic Diseases2018134
26Microvessel density in prostate carcinomaProstate Cancer and Prostatic Diseases2002133
27A potential novel marker for human prostate cancer: voltage-gated sodium channel expression in vivoProstate Cancer and Prostatic Diseases2005133
28Metabolic syndrome and lower urinary tract symptoms: the role of inflammationProstate Cancer and Prostatic Diseases2013132
29Meta-analysis of metabolic syndrome and prostate cancerProstate Cancer and Prostatic Diseases2017130
30miR-148a is an androgen-responsive microRNA that promotes LNCaP prostate cell growth by repressing its target CAND1 expressionProstate Cancer and Prostatic Diseases2010128
31A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomyProstate Cancer and Prostatic Diseases2014128
32The microbiome in prostate inflammation and prostate cancerProstate Cancer and Prostatic Diseases2018125
33Obese men have higher-grade and larger tumors: an analysis of the duke prostate center databaseProstate Cancer and Prostatic Diseases2009124
34Chronic prostatitis/chronic pelvic pain syndrome: a review of evaluation and therapyProstate Cancer and Prostatic Diseases2016122
35PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challengesProstate Cancer and Prostatic Diseases2016121
36The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancerProstate Cancer and Prostatic Diseases2005120
37Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysisProstate Cancer and Prostatic Diseases2017120
38Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapyProstate Cancer and Prostatic Diseases2011117
39Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancerProstate Cancer and Prostatic Diseases2014116
40A double-blind, placebo-controlled randomised trial evaluating the effect of a polyphenol-rich whole food supplement on PSA progression in men with prostate cancer—the UK NCRN Pomi-T studyProstate Cancer and Prostatic Diseases2014116
41Soy isoflavone genistein in prevention and treatment of prostate cancerProstate Cancer and Prostatic Diseases2008115
42Increased dietary and circulating lycopene are associated with reduced prostate cancer risk: a systematic review and meta-analysisProstate Cancer and Prostatic Diseases2017114
43The emerging role of the PI3-K-Akt pathway in prostate cancer progressionProstate Cancer and Prostatic Diseases2005113
44Therapeutic potential of curcumin in human prostate cancer—I. curcumin induces apoptosis in both androgen-dependent and androgen-independent prostate cancer cellsProstate Cancer and Prostatic Diseases2000109
45Novel role for the transient receptor potential channel TRPM2 in prostate cancer cell proliferationProstate Cancer and Prostatic Diseases2010107
46The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysisProstate Cancer and Prostatic Diseases2014106
47Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamideProstate Cancer and Prostatic Diseases1999104
48Multiparametric MRI is helpful to predict tumor focality, stage, and size in patients diagnosed with unilateral low-risk prostate cancerProstate Cancer and Prostatic Diseases2011103
49Oxidative stress in prostate cancer: changing research concepts towards a novel paradigm for prevention and therapeuticsProstate Cancer and Prostatic Diseases2013103
50Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus ProjectProstate Cancer and Prostatic Diseases2017103